TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25331375

Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) for 6 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Obese participants
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (non-obese participants)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Whole body fat oxidation
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Whole body carbohydrate oxidation
Number of subjects: 34
Study: 24057149

Group type: EXPERIMENTAL
Intervention: Intravenous amantadine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 21463139

Group type: EXPERIMENTAL
Intervention: Cabazitaxel plus prednisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel-based therapy
Number of subjects: 0
Study: 18261733

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 5804

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5804
Study: 17001217

Group type: EXPERIMENTAL
Intervention: Smoking prevalence
Number of subjects: 2989

Group type: EXPERIMENTAL
Intervention: Hypertension prevalence
Number of subjects: 2989

Group type: EXPERIMENTAL
Intervention: Obesity prevalence
Number of subjects: 2989

Group type: EXPERIMENTAL
Intervention: High total cholesterol prevalence
Number of subjects: 2989

Group type: EXPERIMENTAL
Intervention: High low-density lipoprotein (LDL) cholesterol prevalence
Number of subjects: 2989

Group type: EXPERIMENTAL
Intervention: Low high-density lipoprotein (HDL) cholesterol prevalence
Number of subjects: 2989

Group type: EXPERIMENTAL
Intervention: Diabetes prevalence
Number of subjects: 2989

Group type: EXPERIMENTAL
Intervention: Population attributable risks for high total cholesterol, hypertension, and large waist-to-hip ratio
Number of subjects: 2989
Study: 12940398

Group type: EXPERIMENTAL
Intervention: Group-mediated cognitive-behavioral (GMCB) intervention
Number of subjects: 147

Group type: COMPARATOR
Intervention: Standard exercise therapy
Number of subjects: 147
Study: 10852328

Group type: EXPERIMENTAL
Intervention: Clodronate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 9327311

Group type: EXPERIMENTAL
Intervention: fentanyl infusion + diazepam + sodium nitroprusside (SNP)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: fentanyl infusion + isoflurane
Number of subjects: 66

Group type: COMPARATOR
Intervention: fentanyl infusion + diazepam
Number of subjects: 66
Study: 7968323

Group type: EXPERIMENTAL
Intervention: Vecuronium with a priming dose of 0.1 mg/kg followed by 0.09 mg/kg (Gp1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Vecuronium with a priming dose of 0.1 mg/kg followed by 0.14 mg/kg (Gp2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Vecuronium with a priming dose of 0.1 mg/kg followed by 0.19 mg/kg (Gp3)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Vecuronium without a priming dose followed by 0.1 mg/kg (Gp4)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Vecuronium without a priming dose followed by 0.15 mg/kg (Gp5)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Vecuronium without a priming dose followed by 0.2 mg/kg (Gp6)
Number of subjects: 90
Study: 3897470

Group type: EXPERIMENTAL
Intervention: BCOP (cyclophosphamide, vincristine, prednisone plus BCNU)
Number of subjects: 296

Group type: COMPARATOR
Intervention: CHOP (doxorubicin)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: BCOP
Number of subjects: 296

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 296
Study: 31124719

Group type: EXPERIMENTAL
Intervention: Telephone communication and task prioritization training (group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Untrained final year students (group B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Training session on telephone communication and task prioritization (group A)
Number of subjects: 50
Study: 28190719

Group type: EXPERIMENTAL
Intervention: Three-component smoking cessation intervention (physician advice, nicotine replacement therapy, and telephone-based quitline referral)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Physician advice
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 156
Study: 26227096

Group type: EXPERIMENTAL
Intervention: 600 mg linezolid infusion over 0.5 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 600 mg linezolid infusion over 2 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 600 mg linezolid infusion over 4 hours
Number of subjects: 12
Study: 24119833

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg by mouth
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 21091391

Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin (PRM; Circadin 2 mg)
Number of subjects: 930

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 930
Study: 19176534

Group type: EXPERIMENTAL
Intervention: Antepartum continuous epidural therapy (ACET) with 0.04, 0.06, 0.08, and 0.1% ropivacaine at 10 ml h(‐1) for 24 h.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (saline) after ACET.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Antepartum continuous epidural therapy (ACET) with 0.1% ropivacaine until delivery.
Number of subjects: 10
Study: 18173095

Group type: EXPERIMENTAL
Intervention: OP-lycopene (8 mg lycopene/day for 2 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: non-OP-lycopene (8 mg lycopene/day for 2 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: OP-lycopene
Number of subjects: 20

Group type: COMPARATOR
Intervention: OP-placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: non-OP-placebo
Number of subjects: 20
Study: 15469204

Group type: EXPERIMENTAL
Intervention: Quetiapine (50 mg/day titrated to 500 mg/day, maintained or increased to 750 mg/day)
Number of subjects: 12
Study: 12804167

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (specifics not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9802253

Group type: EXPERIMENTAL
Intervention: Kinetic Energy (KE) display
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Time Headway (TH) display
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 7653005

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 0
Study: 2096128

Group type: EXPERIMENTAL
Intervention: 400 mg cimetidine twice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: 800 mg cimetidine once daily (bedtime)
Number of subjects: 40
Study: 626718

Group type: EXPERIMENTAL
Intervention: Planned delivery group
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 264
Study: 30426133

Group type: EXPERIMENTAL
Intervention: Mechanical inspiration and expiration exercise
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional dysphagia therapy
Number of subjects: 36
Study: 28976450

Group type: EXPERIMENTAL
Intervention: Always experienced simulated mortality (always death)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Never experienced simulated mortality (never death)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Variable simulated mortality based on performance (variable death)
Number of subjects: 50
Study: 25335860

Group type: EXPERIMENTAL
Intervention: Netazepide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of netazepide and rabeprazole
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 30
Study: 23396459

Group type: EXPERIMENTAL
Intervention: Exposure to mobile phone electromagnetic fields for 60 minutes
Number of subjects: 0
Study: 21258269

Group type: EXPERIMENTAL
Intervention: Intimate partner violence (IPV)
Number of subjects: 717

Group type: COMPARATOR
Intervention: Depressive symptoms and drug use before sex
Number of subjects: 717
Study: 19681775

Group type: EXPERIMENTAL
Intervention: Glutamine (0.5 g/kg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (Control Group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Amino acids solution (Control Group)
Number of subjects: 60
Study: 17374650

Group type: EXPERIMENTAL
Intervention: Fruit and vegetable diet (approximately 10 servings/d for 2 weeks)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Basal diet (fruit- and vegetable-free)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Fruit and vegetable diet (for women with 7/7 genotype)
Number of subjects: 63
Study: 15479889

Group type: EXPERIMENTAL
Intervention: High intensity weightbearing exercises
Number of subjects: 281

Group type: COMPARATOR
Intervention: Usual care physical therapy (UC)
Number of subjects: 281
Study: 11715159

Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: No vaccine
Number of subjects: 0
Study: 9591170

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (40-50% of 1 RM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-intensity exercise (75-85% of 1 RM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (not specifically defined)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (20 min)
Number of subjects: 0
Study: 7605232

Group type: EXPERIMENTAL
Intervention: Quinidine (QG) - i.v. digital + quinidine up to 600 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Procainamide (PG) - i.v. digital + i.v. procainamide, 10 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amiodarone (AG) - i.v. amiodarone, 5 mg/kg
Number of subjects: 60
Study: 3291072

Group type: EXPERIMENTAL
Intervention: Diribiotin CK
Number of subjects: 56
Study: 31931532

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 341
Study: 30207488

Group type: EXPERIMENTAL
Intervention: Enzalutamide after chemotherapy
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Enzalutamide after chemotherapy in abiraterone-pretreated patients
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Enzalutamide after chemotherapy in abiraterone-naive patients
Number of subjects: 209
Study: 28764752

Group type: EXPERIMENTAL
Intervention: Facilitated knowledge translation (KT) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive KT intervention
Number of subjects: 0
Study: 26261113

Group type: EXPERIMENTAL
Intervention: Team-based learning (TBL) sessions on topics of diarrhea, fever of unknown origin, urinary tract infection
Number of subjects: 88

Group type: COMPARATOR
Intervention: Self-study on the same topics without attending TBL sessions
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Team-based learning (TBL) sessions
Number of subjects: 88
Study: 23154636

Group type: EXPERIMENTAL
Intervention: Mozart music
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Dream Theater music
Number of subjects: 55

Group type: COMPARATOR
Intervention: No music
Number of subjects: 55
Study: 21624142

Group type: EXPERIMENTAL
Intervention: mHealth cardiac rehabilitation program delivered via mobile phones and the Internet over six months.
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual cardiac rehabilitation care.
Number of subjects: 170
Study: 18573775

Group type: EXPERIMENTAL
Intervention: Self-administered decision aid (DA) booklet about outcomes of biennial faecal occult blood testing (FOBT) screening
Number of subjects: 314

Group type: COMPARATOR
Intervention: Government consumer guidelines (G)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Self-administered decision aid (DA)
Number of subjects: 314
Study: 17131458

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich fruit juices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polyphenol mixtures in vitro
Number of subjects: 0
Study: 14701887

Group type: EXPERIMENTAL
Intervention: Guideline-based open access urological investigation service for LUTS
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Guideline-based open access urological investigation service for LUTS and MH
Number of subjects: 959

Group type: COMPARATOR
Intervention: Guideline-based open access urological investigation service
Number of subjects: 959
Study: 10678548

Group type: COMPARATOR
Intervention: Valsartan 160 mg once daily (group 1)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Valsartan 80 mg once daily plus benazepril 5 or 10 mg once daily (group 2)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Valsartan 160 mg once daily plus benazepril 5 or 10 mg once daily (group 3)
Number of subjects: 108
Study: 9213834

Group type: EXPERIMENTAL
Intervention: Doxophylline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 20
Study: 8066473

Group type: EXPERIMENTAL
Intervention: Regular sauna baths
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 25

Group type: COMPARATOR
Intervention: Heavy exertion
Number of subjects: 25
Study: 2686413

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 51

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 51
Study: 999485

Group type: EXPERIMENTAL
Intervention: True feedback condition
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: No feedback condition
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo feedback condition
Number of subjects: 18
Study: 31241511

Group type: EXPERIMENTAL
Intervention: HIV prevention intervention
Number of subjects: 65
Study: 28262253

Group type: EXPERIMENTAL
Intervention: Onstep technique
Number of subjects: 259

Group type: COMPARATOR
Intervention: Lichtenstein technique
Number of subjects: 259
Study: 25783468

Group type: COMPARATOR
Intervention: GnRH(AG) + PL
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: GnRH(AG) + E2
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: GnRH(AG) + PL + Ex
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: GnRH(AG) + E2 + Ex
Number of subjects: 70
Study: 23912021

Group type: EXPERIMENTAL
Intervention: Breast milk warmed using water baths (temperature range: 23.3°C to 45.5°C at start, 23.8°C to 38.4°C at removal)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Refrigerated breast milk (temperature range: 3.8°C to 27.1°C warmed to 21.8°C to 36.2°C at feeding time)
Number of subjects: 33
Study: 21621673

Group type: EXPERIMENTAL
Intervention: 0% BWS
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 25% BWS
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50% BWS
Number of subjects: 12
Study: 19663597

Group type: EXPERIMENTAL
Intervention: Paromomycin 11 mg/kg/day for 14 days (Group A)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Paromomycin 11 mg/kg/day for 21 days (Group B)
Number of subjects: 329
Study: 16728716

Group type: EXPERIMENTAL
Intervention: Low-dose ethanol (0.5 g/kg body weight per day)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Morphine (15 mug/kg body weight per hour)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg four times daily)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 15298657

Group type: EXPERIMENTAL
Intervention: Paroxetine 20-50 mg/day
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study: 11736682

Group type: EXPERIMENTAL
Intervention: 1 mg/kg ropivacaine
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 2 mg/kg ropivacaine
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 3 mg/kg ropivacaine
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 1-3 mg/kg ropivacaine
Number of subjects: 43
Study: 8564629

Group type: EXPERIMENTAL
Intervention: Salmeterol, 50 micrograms, dry powder inhalation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1845606

Group type: EXPERIMENTAL
Intervention: Beef tallow
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cocoa butter
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Butter fat
Number of subjects: 10
Study: 6813482

Group type: EXPERIMENTAL
Intervention: Sodium aurothiomalate (GSTM)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Auranofin (AF)
Number of subjects: 112
Study: 31208690

Group type: EXPERIMENTAL
Intervention: Moodivate (self-help behavioral activation mobile app)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: MoodKit (active control cognitive-behavioral therapy-based mobile app)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Treatment as usual (TAU; no app)
Number of subjects: 52
Study: 28668664

Group type: EXPERIMENTAL
Intervention: Paro (companion robot)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 30
Study: 26204125

Group type: COMPARATOR
Intervention: Hand Expression (HE)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Electric Expression (EE)
Number of subjects: 26
Study: 23691965

Group type: EXPERIMENTAL
Intervention: Excessive sensory innervation to the glabrous skin AVS in FM patients
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: SNRI compounds
Number of subjects: 33

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 33
Study: 21496324

Group type: EXPERIMENTAL
Intervention: Geoadditive models assessing spatial variation of HIV infections
Number of subjects: 3469
Study: 19140909

Group type: EXPERIMENTAL
Intervention: Dofetilide therapy
Number of subjects: 16
Study: 17563127

Group type: EXPERIMENTAL
Intervention: COB + enfuvirtide
Number of subjects: 157

Group type: COMPARATOR
Intervention: COB + PI
Number of subjects: 157

Group type: COMPARATOR
Intervention: COB + NRTI + PI
Number of subjects: 157
Study: 15339848

Group type: EXPERIMENTAL
Intervention: Recombinant human activated protein C (rhAPC)
Number of subjects: 0
Study: 11606840

Group type: EXPERIMENTAL
Intervention: Gd‐BOPTA
Number of subjects: 257

Group type: COMPARATOR
Intervention: Gd‐DTPA
Number of subjects: 257
Study: 9675564

Group type: EXPERIMENTAL
Intervention: Estradiol valeriante + norethisterone acetate (Group A)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Estradiol valeriante + promegestone (Group B)
Number of subjects: 14
Study: 7925889

Group type: EXPERIMENTAL
Intervention: Pari LC nebulizer operated intermittently
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pari LC nebulizer operated continuously
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pari LL nebulizer operated intermittently
Number of subjects: 10
Study: 2166142

Group type: COMPARATOR
Intervention: Cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vindesine and cisplatin (VP) chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study: 364409

Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg per day for 2 months)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31983513

Group type: EXPERIMENTAL
Intervention: Caloric restriction with sleep extension
Number of subjects: 52

Group type: COMPARATOR
Intervention: Caloric restriction without sleep extension
Number of subjects: 52
Study: 30558476

Group type: EXPERIMENTAL
Intervention: Hypoxic training (14% FiO2, 30-min handgrip training, 4 times a week for 4 weeks)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normoxic training (30-min handgrip training, 4 times a week for 4 weeks)
Number of subjects: 9
Study: 28949973

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone pessaries (100 mg)
Number of subjects: 787

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 787
Study: 25829298

Group type: EXPERIMENTAL
Intervention: Olodaterol 2 μg
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Olodaterol 5 μg
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Olodaterol 10 μg
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Olodaterol 20 μg
Number of subjects: 405

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study: 22549084

Group type: EXPERIMENTAL
Intervention: Kettlebell training for 10 weeks, structured in a group setting for 2 days per week.
Number of subjects: 37
Study: 20876189

Group type: EXPERIMENTAL
Intervention: S1 strategy (group information and referral for screening)
Number of subjects: 1276

Group type: EXPERIMENTAL
Intervention: S2 strategy (group information and in situ screening)
Number of subjects: 1276

Group type: COMPARATOR
Intervention: S0 strategy (no intervention)
Number of subjects: 1276
Study: 19884816

Group type: EXPERIMENTAL
Intervention: Pantoprazole, clarithromycin, and amoxicillin (PCA) for 14 days
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Ranitidine-bismuth citrate, clarithromycin, and amoxicillin (RCA) for 14 days
Number of subjects: 98
Study: 17265148

Group type: EXPERIMENTAL
Intervention: 5 mg of olanzapine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 15145926

Group type: EXPERIMENTAL
Intervention: Vigorous physical activity (≥6 metabolic equivalents) and high calcium intake
Number of subjects: 76

Group type: COMPARATOR
Intervention: Total physical activity
Number of subjects: 76
Study: 11224891

Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone sodium succinate (MPSS)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 9148142

Group type: EXPERIMENTAL
Intervention: Encouragement to use condoms for HIV/STD prevention
Number of subjects: 0
Study: 8220058

Group type: EXPERIMENTAL
Intervention: Saliva test pipeline procedure
Number of subjects: 1582

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1582
Study: 3085698

Group type: EXPERIMENTAL
Intervention: Nitradisc 32 mg patch
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Transiderm‐Nitro 50 mg patch
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nitro-Dur 104 mg patch
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nitrobid 2% ointment
Number of subjects: 24
Study: 29732536

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment of Insomnia (CBTi)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham control intervention
Number of subjects: 0
Study: 27222436

Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation (tVNS) during the extinction phase
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham stimulation during the extinction phase
Number of subjects: 31